EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
mRNA Platforms as Diagnostics and Therapeutics for Human Infertility Treatments
Associate Professor, Department of Biology, Khalifa University
Junaid Kashir is an Associate Professor in the Department of Biology at Khalifa University and
has previously chaired multiple researchadministrative committees He has been heavily
involved in multiple programs for training graduate clinical embryology students Dr Kashirs
research aims to develop therapeuticdiagnostic interventions to treat infertility and understand
embryology
Articles
New Paradigm in Combination Therapy of siRNA with Chemotherapeutic Drugs towards Cancer Targeting
Cancer is a dynamic cellular process in which complex interplay of cellular interactions and genetic alterations characterised by multiple gene mutations occur The complexity of signaling pathways makes treatment of cancer difficult due to altered cellular mechanisms which cause cell death This calls for treatment modalities which can target the molecular mechanisms involved in cancer patho phys...
Research Insights
MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells
Mammalian cells release different types of vesicles collectively termed extracellular vesicles EVs EVs contain cellular microRNAs miRNAs with an apparent potential to deliver their miRNA cargo to recipient cells to affect the stability of individual mRNAs and the cells transcriptome
Case Studies
Labile Biologics - Stable Aqueous Formulation of Recombinant Factor VIII
Challenge All marketed Factor VIII products are lyophilised preparations produced by either recombinant technology or purified from pooled plasma The preparations are typically stabilised by addition of sugars Administration of the lyophilised product is a very complex procedure involving a number
Techno Trends
Breakthrough Therapy Lenvima/Keytruda Combo Treats Patients with Advanced Kidney Cancer
Eisais multiple receptor tyrosine kinase inhibitor lenvatinib mesylate Lenvima in combination with Mercks antiprogrammed death therapy pembrolizumab Keytruda received FDAs breakthrough therapy designation for treatment of patients with advanced kidney cancer This is the second breakthrough therapy designation for lenvatinib and the th granted to pembrolizumab Le...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Computational Approach towards Designing Potent Inhibitors for Tuberculosis
Soumyadip Das received a BSc degree from University of Calcutta, India, in 2017 and a MSc degree from Vellore Institute of Technology, Vellore, India, in 2019. He is currently pursuing his PhD degree from Vellore Institute of Technology, Vellore, India, under the supervision of Dr. Kaushik Chanda. His research interest includes diversity-oriented synthesis, anticancer drug design, and nanocatalysis.
Balamurali MM, was awarded the Master’s degree in Chemistry, by Madurai Kamaraj University, Tamil Nadu, India in 1999. He persuaded his doctoral research in Photophysical Chemistry at Indian Institute of Technology Kanpur, under the supervision of Prof. Sneh Kumar Dogra. In 2005, he was awarded the CSIR research associate fellowship and continued his postdoctoral research in Prof. Raghavan Varadarajan’s group at Indian Institute of Science Bangalore.
Kaushik Chanda, obtained his MSc in Organic Chemistry from Gauhati University, Assam India in 2001. Subsequently worked as a Senior Research Fellow in ICAR-NATP funded project in St Anthonys College, Shillong, India from 2002-2005. In 2006, he moved to Taiwan for pursuing PhD in Applied Chemistry from National Chiao Tung University under the guidance of Prof Chung Ming Sun on a topic of Combinatorial Chemistry.
Reshaping the Clinical Trial Model
Anna Hayes is a senior data management leader (At Veramed) with nearly 20 years of experience in clinical research. She specializes in biometrics strategy, innovation, and operational excellence, driving smarter oversight and data-driven trial execution. Anna is passionate about integrating people, processes, and technology to future-proof clinical trials and elevate data quality.
The Role of Technology in Continued Process Verification 4.0
Dr. Kavita is a seasoned leader in the field of data and insights, with over 20 years of invaluable experience. She is a result-oriented solution designer in data warehouse and big data analytics. Drawing from her extensive in multinational organisations IBM, Capgemini, and others, Kavita has successfully overseen numerous large and intricate projects. Her expertise lies in effectively leveraging her robust technical knowledge in areas such as data warehousing and business intelligence to drive impactful outcomes. Under Dr. Kavita's exceptional leadership, the CaliberAPQR product has achieved outstanding recognition.
Incipient Biopharmaceutical Claims of Milk Derived Exosomes
Rakesh K. Tekade is a formulation researcher with of teaching and research experience. He has an explicit experience of over 10 years in teaching various modules for Ph.D, Masters & Bachelors students (@ Universities based in USA, UK, Malaysia, & India). He currently serving as Associate Professor at NIPER-Ahmedabad (An Institute of National Importance Government of India). Prior to this, Dr. Tekade was faculty at International Medical University, Kuala Lumpur, Malaysia. He took his postdoctoral trainings from UT Southwestern Medical Centre, Dallas, Texas, USA and University of Hawaii, Hilo, Hawaii, USA. He is a recipient of Commonwealth Fellowship at University of Central Lancashire, Preston, UK. Recently, Dr Tekade has been listed as Top 2% researcher in the field of Pharmacy and Pharmacology, by Stanford University, USA.
Nupur Vasdev is currently pursuing her PhD in the department of pharmaceutics from NIPER-Ahmedabad. She has completed M.S (Pharm.) in pharmaceutics from NIPER-Raebareli. She is currently working on targeted nano particulate drug delivery for obesity and cancer. Her research focus also includes surface modified exosome drug delivery for cancer and obesity.
Manisha Choudhary is currently pursuing her M.S. (Pharm) in Pharmaceutics at NIPER-Ahmedabad, India. She is currently working on aptamer decorated nanomaterials for improving the targeting. Her work majorly focuses on the improvement of the stability, targeting and robustness of aptamer conjugated nanomaterials for cancer treatment. Her work also focusses on the extraction of natural derived exosomes.
Suryanarayana Polaka is currently pursuing his PhD at NIPER-Ahmedabad, India. He is working in targeted drug delivery systems for the treatment of rheumatoid arthritis and wound healing. He also works on exosome mediated drug delivery. He co-authored 10 peer-reviewed publications in international journals, contributed > 7 international reference book chapters.
Professor Kiran Kalia is a currently serving as Director and Professor at NIPER-Ahmedabad. Her work basically focused on the Proteomic markers for diabetic nephropathy, diabetic retinopathy and metal toxicity studies. Recently she started exploring the exosomes mediated drug delivery for delivering the genes for treating various ailments like cancer, wounds and diabetic nephropathy.
QSAR - Changing the Landscape of Antidiabetic Drug Discovery
Smriti Sharma Bhatia is an associate professor of chemistry at Miranda House, University of Delhi, India. Her academic and research interests include Computational chemistry and drug design. Currently, her research group is focused on the design of oral drug formulations for Type 2 diabetes mellitus. She is a popular science communicator.
press releasesRead more...
First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
Clarity PharmaceuticalsASX CU Clarity or Company a clinicalstage radiopharmaceutical company with a mission to develop nextgeneration products that improve treatment outcomes for patients with cancer is pleased to announce that
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
Pfizer Inc NYSE PFE and Blackstone Life Sciences Blackstone today announced a strategic cofunding agreement under which funds managed by Blackstone will pay up to a total of billion of development
Circio and Solid Biosciences enter collaboration to evaluate circVec and POLARIS-101 technology for Genetic Heart Disease
Circio Holding ASA OSE CRNA a biotechnology company developing novel circular RNA expression technology for gene and cell therapy today announces a research collaboration with Solid Biosciences Inc
EirGenix and Merck enter Partnership to Strengthen Global Biologics Development Through Integrated BioReliance® Testing and Regulatory Support
EirGenix Inc and Merck have signed a nonlegally binding memorandum of understanding MOU to support EirGenixs IND and BLA enabling biologics pipeline development The MOU outlines Merck as one of EirGenixs preferred contract testing services vendors providing comprehensive BioReliance services
ProBio Enters Exclusive Global Licensing Agreement with AbTis to Develop Next-Generation ADC Asset
ProBio a global contract research development and manufacturing organization CRDMO today announced that it has entered into an exclusive global licensing agreement with AbTis Co Ltd
AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder
In a world where patients with CDKL deficiencies can suffer to epileptic seizures a day a contract biopharmaceutical manufacturer and a parentfounded foundation will partner on earlystage
EventsRead more...
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
LATEST NEWSRead more...
Immuneering Enters into Collaboration with Astellas to Evaluate Combination Therapies for Pancreatic Cancer
Immuneering has entered into a clinical trial collaboration and supply agreement with Astellas Pharma to evaluate investigational combination therapies for patients with pancreatic cancer
Eppendorf Invests €40 Million in New Manufacturing Facility in Penang, Malaysia
Eppendorf has started construction of a new manufacturing facility at Bandar Cassia Technology Park in Penang Malaysia
Lilly Invests US$3.5 Billion in New Manufacturing Facility for Obesity Medicines in Pennsylvania
Eli Lilly and Company has started construction of a US billion manufacturing facility in Lehigh Valley Pennsylvania as part of its plans to expand medicine production in the United States The new site is one of manufacturing facilities
Natera Enters into Collaboration with Incyte for Phase II Trial in Colorectal Cancer
Natera a precision medicine company has entered into a clinical collaboration with Incyte to support a new Phase II study evaluating an investigational treatment for colorectal cancer CRC
Shionogi Enters into Licence Agreement with Link for Antibiotic Cefiderocol
Shionogi has entered into a licence agreement with Link Healthcare Singapore to develop and commercialise cefiderocol in Singapore and Malaysia
IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours
IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...
